The Added Value of Assessing Ligand-Receptor Binding Kinetics in Drug Discovery

ACS Medicinal Chemistry Letters

Volumn 7, Issue 9, 2016, Pages 819-821

  Guo, Dong ^a   Heitman, Laura H ^b   Ijzerman, Adriaan P ^b  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITY; BINDING KINETICS; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; RECEPTOR BINDING ASSAY; REVIEW; TRANSLATIONAL RESEARCH;

EID: 84986277612     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00273     Document Type: Review

References (13)

1. Guo, D.; Heitman, L. H.; IJzerman, A. P. The Role of Target Binding Kinetics in Drug Discovery ChemMedChem 2015, 10 (11) 1793-1796 10.1002/cmdc.201500310
2. Guo, D.; Hillger, J. M.; IJzerman, A. P.; Heitman, L. H. Drug-target residence time-a case for G protein-coupled receptors Med. Res. Rev. 2014, 34 (4) 856-892 10.1002/med.21307
3. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 2006, 5 (9) 730-9 10.1038/nrd2082
4. Copeland, R. A. The drug-target residence time model: a 10-year retrospective Nat. Rev. Drug Discovery 2016, 15 (2) 87-95 10.1038/nrd.2015.18
5. Dahl, G.; Akerud, T. Pharmacokinetics and the drug-target residence time concept Drug Discovery Today 2013, 18 (15-16) 697-707 10.1016/j.drudis.2013.02.010
6. Vauquelin, G.; Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 2010, 161 (3) 488-508 10.1111/j.1476-5381.2010.00936.x
7. Walkup, G. K.; You, Z.; Ross, P. L.; Allen, E. K.; Daryaee, F.; Hale, M. R.; O'Donnell, J.; Ehmann, D. E.; Schuck, V. J.; Buurman, E. T.; Choy, A. L.; Hajec, L.; Murphy-Benenato, K.; Marone, V.; Patey, S. A.; Grosser, L. A.; Johnstone, M.; Walker, S. G.; Tonge, P. J.; Fisher, S. L. Translating slow-binding inhibition kinetics into cellular and in vivo effects Nat. Chem. Biol. 2015, 11 (6) 416-23 10.1038/nchembio.1796
8. Guo, D.; Dijksteel, G. S.; van Duijl, T.; Heezen, M.; Heitman, L. H.; IJzerman, A. P. Equilibrium and kinetic selectivity profiling on the human adenosine receptors Biochem. Pharmacol. 2016, 105, 34-41 10.1016/j.bcp.2016.02.018
9. Ayaz, P.; Andres, D.; Kwiatkowski, D. A.; Kolbe, C. C.; Lienau, P.; Siemeister, G.; Lucking, U.; Stegmann, C. M. Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9 ACS Chem. Biol. 2016, 11 (6) 1710-9 10.1021/acschembio.6b00074
10. Klein Herenbrink, C.; Sykes, D. A.; Donthamsetti, P.; Canals, M.; Coudrat, T.; Shonberg, J.; Scammells, P. J.; Capuano, B.; Sexton, P. M.; Charlton, S. J.; Javitch, J. A.; Christopoulos, A.; Lane, J. R. The role of kinetic context in apparent biased agonism at GPCRs Nat. Commun. 2016, 7, 10842 10.1038/ncomms10842
11. Hothersall, J. D.; Brown, A. J.; Dale, I.; Rawlins, P. Can. residence time offer a useful strategy to target agonist drugs for sustained GPCR responses? Drug Discovery Today 2016, 21 (1) 90-6 10.1016/j.drudis.2015.07.015
12. Zhou, X.; Huntjens, D.; Gilissen, R. A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics CPT: Pharmacometrics Syst. Pharmacol. 2015, 4 (11) 650-9 10.1002/psp4.12035
13. de Witte, W. E.; Wong, Y. C.; Nederpelt, I.; Heitman, L. H.; Danhof, M.; van der Graaf, P. H.; Gilissen, R. A.; de Lange, E. C. Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients Expert Opin. Drug Discovery 2016, 11 (1) 45-63 10.1517/17460441.2016.1100163